STOCK TITAN

Glaukos Corporation - GKOS STOCK NEWS

Welcome to our dedicated page for Glaukos Corporation news (Ticker: GKOS), a resource for investors and traders seeking the latest updates and insights on Glaukos Corporation stock.

Glaukos Corporation (NYSE: GKOS) is a prominent ophthalmic medical technology company specializing in breakthrough products and procedures aimed at transforming the treatment of glaucoma. As one of the leading causes of blindness globally, glaucoma demands innovative solutions, and Glaukos has pioneered micro-invasive glaucoma surgery (MIGS) to revolutionize traditional management paradigms.

The company's flagship product, the iStent Trabecular Micro-Bypass Stent, launched in the United States in 2012, is celebrated for being the smallest medical device ever approved by the FDA, measuring a mere 1.0 mm long and 0.33 mm wide. This device is designed to reduce intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma when used in conjunction with cataract surgery.

Building on the success of the iStent, Glaukos is developing a comprehensive and proprietary portfolio of injectable micro-scale therapies targeting the entire spectrum of glaucoma disease states and progression. The pipeline includes the iStent SA Trabecular Micro-Bypass System, a two-stent product with a different auto-injection inserter for standalone procedures.

In June 2015, Glaukos successfully completed its initial public offering, and its shares are now publicly traded on the New York Stock Exchange. The company continues to innovate and expand its product offerings, maintaining its position as a leader in the ophthalmic medical technology field.

  • Recent achievements include the expansion of their product pipeline and the ongoing development of next-generation MIGS devices.
  • Current projects focus on enhancing the efficacy and accessibility of glaucoma treatments worldwide.
  • Partnerships with leading ophthalmic institutions and research organizations fuel Glaukos' mission to improve patient outcomes.

Glaukos Corporation remains committed to transforming glaucoma treatment through technological innovation and strategic growth.

Rhea-AI Summary
Glaukos Corporation (NYSE: GKOS) received FDA approval for iDose TR, a revolutionary, micro-invasive, injectable treatment for glaucoma. The drug is designed to deliver long-duration, intracameral therapy for glaucoma patients. The FDA approval is based on robust Phase 3 clinical trials, and the company plans to commence commercial launch activities in the first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.36%
Tags
-
Rhea-AI Summary
Glaukos Corporation (NYSE: GKOS) will participate in the Stifel Healthcare Conference on November 14, 2023, at 10:55 a.m. ET in New York City. The event will be available via live and archived webcast on the Glaukos website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.67%
Tags
none
-
Rhea-AI Summary
Glaukos Corporation (NYSE: GKOS) announced its financial results for Q3 2023. Net sales increased by 10% YoY to $78.0 million. Glaucoma net sales rose by 9% YoY to $58.3 million, and Corneal Health net sales increased by 12% YoY to $19.7 million. Gross margin was approximately 76%, and non-GAAP gross margin was approximately 83%. The company raised its 2023 net sales guidance to $307 million to $310 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.58%
Tags
Rhea-AI Summary
Glaukos Corporation will feature its technologies in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting. The company will exhibit onsite at booth #1630. Key presentations include studies on the efficacy and safety of Glaukos' intraocular implants for glaucoma treatment, as well as innovations in collagen cross-linking for corneal health. The AAO Annual Meeting is a significant event in the ophthalmic industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.07%
Tags
none
-
Rhea-AI Summary
Glaukos Corporation to release Q3 2023 financial results and hold conference call and webcast
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.99%
Tags
-
Rhea-AI Summary
Glaukos Corporation to participate in Wells Fargo Healthcare Conference on September 6, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
-
Rhea-AI Summary
Glaukos Corporation (NYSE: GKOS) announced a collaboration and marketing agreement with Radius XR, Inc. to market the Radius XR™ wearable patient engagement and diagnostic system in the US. The system aims to enable more efficient detection of eye diseases and better management of sight-threatening conditions, providing medical professionals with accurate diagnostics and patient engagement tools. Glaukos will be the exclusive sales agent for the system, leveraging its expertise to drive greater patient access.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
none
-
Rhea-AI Summary
Glaukos Corporation (NYSE: GKOS) to discuss second quarter 2023 financial results in conference call and webcast. Management will address novel therapies for glaucoma, corneal disorders, and retinal diseases. Investors can participate by dialing 888-210-2212 (U.S.) or 646-960-0390 (International) and entering Conference ID 7935742.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags

FAQ

What is the current stock price of Glaukos Corporation (GKOS)?

The current stock price of Glaukos Corporation (GKOS) is $150.88 as of December 20, 2024.

What is the market cap of Glaukos Corporation (GKOS)?

The market cap of Glaukos Corporation (GKOS) is approximately 7.9B.

What is Glaukos Corporation?

Glaukos Corporation is an ophthalmic medical technology company focused on developing breakthrough products and procedures for treating glaucoma.

What is the iStent Trabecular Micro-Bypass Stent?

The iStent is a tiny medical device used to reduce intraocular pressure in patients with mild-to-moderate open-angle glaucoma, especially during cataract surgery.

When did Glaukos go public?

Glaukos completed its initial public offering in June 2015 and is traded on the New York Stock Exchange under the symbol GKOS.

What is MIGS?

MIGS stands for micro-invasive glaucoma surgery, a technique pioneered by Glaukos to shift the paradigm in glaucoma treatment.

What is the iStent SA?

The iStent SA is a two-stent system with a different auto-injection inserter, designed for standalone glaucoma procedures.

What recent achievements has Glaukos made?

Recent achievements include expanding their product pipeline and developing next-generation MIGS devices.

What is the significance of Glaukos' products?

Glaukos' products are significant for their innovative approach to reducing intraocular pressure and transforming glaucoma treatment.

Who are Glaukos' partners?

Glaukos partners with leading ophthalmic institutions and research organizations to advance their mission of improving patient outcomes.

What is Glaukos' mission?

Glaukos aims to transform glaucoma treatment through technological innovation and strategic growth.

How does Glaukos continue to innovate?

Glaukos continues to innovate by developing a proprietary portfolio of injectable micro-scale therapies and next-generation MIGS devices.

Glaukos Corporation

NYSE:GKOS

GKOS Rankings

GKOS Stock Data

7.93B
53.37M
3.19%
101.17%
5.1%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
ALISO VIEJO